JW (Cayman) Therapeutics Co. Ltd. (2126) AI Stock Analysis

• Market Cap: HK$1.07B
• Dividend Yield: N/A
• Average Volume (3M): 2.80M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.45
• Revenue Growth: -10.78%
• EPS Growth: 24.88%
• Country: HK
• Employees: 281
• Sector: Healthcare
• Sector Strength: 47
• Industry: Biotechnology
• EPS (TTM): -0.94
• Shares Outstanding: 416,198,460
• 10 Day Avg. Volume: 4,236,252
• 30 Day Avg. Volume: 2,804,519
• PEG Ratio: -0.28
• Price to Book (P/B): 0.85
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -5.08
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 54 Neutral
• Price Target: HK$2.50 ▼(-4.58%Downside)

The stock's overall score is primarily driven by its strong technical performance, suggesting bullish momentum. However, the score is tempered by financial challenges, particularly profitability issues and negative cash flow. Valuation remains a concern due to the negative P/E ratio, reflecting ongoing losses.

JW (Cayman) Therapeutics Co. Ltd. Business Overview & Revenue Model

Company Description

JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, focuses on developing, manufacturing, and commercializing cell-based immunotherapies for hematological cancers and solid tumors. The company offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of a range of hematological cancers. The company's pipeline products include JWCAR129, an autologous CAR-T therapy for the treatment of multiple myeloma; JWATM204, a TCR T-cell therapy candidate for the treatment of HCC; and JWATM203, an autologous T-cell receptor mimic T-cell therapy targeting alpha-fetoprotein for the treatment of hepatocellular carcinoma. JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, the People's Republic of China.

How the Company Makes Money

JW (Cayman) Therapeutics Co. Ltd. generates revenue primarily through the development and commercialization of its proprietary cell-based immunotherapy products. The company earns income by selling its products to healthcare providers, hospitals, and clinics. Additionally, JW Therapeutics may engage in strategic partnerships and collaborations with other biotechnology and pharmaceutical companies, which can provide upfront payments, milestone payments, and royalties. The company might also benefit from government grants and subsidies for research and development activities, contributing to its revenue streams.

JW (Cayman) Therapeutics Co. Ltd. Financial Statement Overview

Summary

The company shows revenue growth but struggles with profitability, indicated by ongoing net losses and negative cash flow. The balance sheet reflects financial stability with a strong cash position, but operational efficiency and profitability need improvement.

Income Statement

The company has shown consistent revenue growth over the years, with a notable increase from 2020 onwards. However, profitability remains a significant issue as the company has reported negative net income and EBIT margins throughout the years, indicating ongoing operational challenges. The gross profit margin has improved slightly, yet the high net losses overshadow these gains.

Balance Sheet

The company's balance sheet is relatively stable with a strong cash position, as indicated by the significant cash and cash equivalents. The debt-to-equity ratio remains low, suggesting conservative leverage. However, the continued net losses have adversely affected the return on equity, which remains negative. The equity ratio indicates a solid equity base compared to total assets, pointing to financial stability despite ongoing losses.

Cash Flow

Operating cash flow has been consistently negative, reflecting challenges in generating cash from operations. The company has managed to maintain a positive cash position largely through financing activities. Free cash flow remains negative, indicating that the company is not yet self-sustaining and relies on external funding to cover operational and capital expenditures.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
158.22M	173.86M	145.70M	30.80M	0.00
	Gross Profit
77.32M	88.22M	58.76M	9.04M	0.00
	EBITDA
-381.58M	-655.75M	-752.27M	-738.70M	-454.04M
	Net Income
-590.62M	-768.00M	-846.13M	-702.33M	-1.66B
Balance Sheet		Total Assets
1.68B	2.15B	2.79B	3.12B	3.78B
	Cash, Cash Equivalents and Short-Term Investments
757.38M	1.01B	1.39B	1.84B	2.63B
	Total Debt
422.40M	318.80M	279.13M	147.03M	123.59M
	Total Liabilities
511.20M	462.26M	437.06M	325.75M	349.76M
	Stockholders Equity
1.17B	1.68B	2.35B	2.79B	3.43B
Cash Flow		Free Cash Flow
-348.87M	-413.00M	-613.60M	-634.28M	-385.24M
	Operating Cash Flow
-333.44M	-398.42M	-536.72M	-561.20M	-261.00M
	Investing Cash Flow
-15.43M	9.90M	-124.08M	-137.13M	-91.91M
	Financing Cash Flow
90.49M	275.00K	112.35M	-30.62M	2.86B

JW (Cayman) Therapeutics Co. Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.62
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2126, the sentiment is Positive. The current price of 2.62 is above the 20-day moving average (MA) of 2.18, above the 50-day MA of 1.82, and above the 200-day MA of 1.63, indicating a bullish trend. The MACD of 0.25 indicates Negative momentum. The RSI at 80.67 is Negative, neither overbought nor oversold. The STOCH value of 95.06 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2126.

JW (Cayman) Therapeutics Co. Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
9966	60 Neutral	HK$6.55B	37.10	9.52%	―	185.36%	―
2616	55 Neutral	HK$5.50B	―	-22.23%	―	-14.17%	76.00%
2126	54 Neutral	HK$1.07B	―	-41.34%	―	-10.78%	24.88%
Sector *	51 Neutral	$7.34B	0.29	-60.38%	2.38%	17.46%	1.71%
2157	49 Neutral	HK$9.96B	―	-51.40%	―	58.75%	-1310.16%
2179	46 Neutral	HK$4.05B	―	-69.97%	―	―	3.30%
6955		HK$7.14B	80.65	4.95%	―	―	―

JW (Cayman) Therapeutics Co. Ltd. Corporate Events

JW Therapeutics Approves License Agreement at EGM

JW (Cayman) Therapeutics Co. Ltd held an Extraordinary General Meeting (EGM) on June 3, 2025, where an ordinary resolution regarding the approval, ratification, and confirmation of a License Agreement was passed unanimously. The resolution’s approval, with 100% of the votes in favor, signifies a strategic move for the company, potentially enhancing its operational capabilities and market position in the biotechnology sector.

JW Therapeutics Advances Cancer Treatment with NMPA Acceptance

JW Therapeutics announced that the National Medical Products Administration of China has accepted the supplemental Biological License Application for Carteyva® as a second-line treatment for relapsed or refractory large B-cell lymphoma in patients ineligible for autologous stem cell transplantation. This development is supported by positive clinical results showing significant response rates and safety, addressing the urgent need for effective treatments for patients who cannot undergo standard therapies. The acceptance of this application could enhance JW Therapeutics’ position in the biotechnology industry and provide new hope for patients with limited treatment options.

JW Therapeutics Announces Extraordinary General Meeting for License Agreement Approval

JW (Cayman) Therapeutics Co. Ltd. has announced an extraordinary general meeting scheduled for June 3, 2025, to approve a License Agreement and related transactions. This meeting is crucial for the company’s strategic operations, potentially impacting its market positioning and stakeholder interests.

JW Therapeutics Announces Closure of Register for Upcoming EGM

JW (Cayman) Therapeutics Co. Ltd. announced the closure of its register of members from May 29 to June 3, 2025, to determine shareholders eligible to attend and vote at the upcoming Extraordinary General Meeting (EGM) on June 3, 2025. This announcement is significant as it outlines the procedural steps for shareholder participation, potentially impacting shareholder engagement and decision-making processes within the company.

JW Therapeutics Announces 2025 Annual General Meeting

JW (Cayman) Therapeutics Co. Ltd. has announced its upcoming annual general meeting scheduled for June 26, 2025, in Shanghai, China. Key agenda items include the adoption of the 2024 financial statements, re-election of directors, re-appointment of Deloitte Touche Tohmatsu as auditors, and approval for directors to manage share-related transactions. This meeting is crucial for setting the company’s strategic direction and ensuring continued governance and financial oversight.

JW Therapeutics Announces License Agreement with Juno Amid Regulatory Approvals

JW (Cayman) Therapeutics Co. Ltd. has entered into a License Agreement with Juno, a substantial shareholder and connected person, to grant a non-exclusive license for its sLVV Manufacturing Process and related know-how for Juno’s cell therapy products globally. This transaction is classified as a connected transaction under Hong Kong’s Listing Rules, requiring independent shareholder approval due to the significant percentage ratio involved. An independent board committee and financial adviser have been appointed to guide shareholders, and an Extraordinary General Meeting (EGM) will be held to seek approval. Juno and its associates will abstain from voting, and the transaction’s effectiveness is contingent upon meeting listing requirements.

JW Therapeutics Grants Over 7 Million Share Options to Employees

JW (Cayman) Therapeutics Co. Ltd. announced the grant of 7,756,183 share options to thirteen eligible employees, including a significant allocation to its CEO and Chairman, Mr. Min Liu. This move is part of the company’s Post-IPO Incentivization Scheme, aimed at aligning the interests of its employees with long-term shareholder value, potentially enhancing employee retention and motivation.

JW Therapeutics Reports 2024 Financial Results Amid Strategic Adjustments

JW (Cayman) Therapeutics Co. Ltd. reported a 9% decrease in revenue for 2024, attributed to optimization strategies and commercial personnel effectiveness programs. Despite the revenue decline, the company anticipates future growth from Carteyva® sales and additional product indications. The company also saw a 24% increase in selling expenses due to exploring new commercialization approaches, which, although costly, enhanced market understanding. R&D expenses dropped by 31.6% due to workforce optimization and reduced material costs, while other gains and losses decreased partly due to reduced license impairment as Eureka initiated a phase II study in the U.S.